Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Conditioning with Cytoxan Increases Protected Cells in HIV Gene Therapy Trial

Administering cyclophosphamide (Cytoxan), a chemotherapy drug toxic to certain immune cells, prior to zinc-finger gene therapy appears to make room for increased proliferation of altered CD4 T-cells lacking the CCR5 co-receptor, researchers reported at the 6th International Workshop on HIV Persistence during Therapy last week in Miami.

alt

Read more:

Antiretroviral Treatment Has Saved Nearly 3 Million Life-years in South Africa

Widespread use of effective antiretroviral therapy (ART) has led to "massive benefits" in hard-hit South Africa, saving an estimated 2.8 million life-years by 2012, and potentially up to 22 million years over the lifetime of treated individuals, according to a modeling study described in the December 3, 2013, advance edition of the Journal of Infectious Diseases.

alt

Read more:

The Lancet/Cell Conference Asks: What Will it Take to Achieve an AIDS-free World?

"What will it take to achieve and AIDS-free world?" was the question on everyone's mind at a small meeting of the same name held November 3-5 at the St. Francis Hotel in San Francisco. A Cell press release stated that the goal of the meeting was to "bridge the gap between researchers and clinicians in a joint effort to identify what needs to be done before an AIDS-free world can go from dream to reality."

alt

Read more:

HIV Re-emerges in Boston Bone Marrow Transplant Patients

Two bone marrow stem cell recipients who had undetectable HIV according to the most sensitive tests for months after an experimental antiretroviral therapy (ART) interruption have experienced viral rebound and had to restart treatment, frustrating hopes for a functional cure, according to a report at the 6th International Workshop on HIV Persistence during Therapy last week in Miami.

alt

Read more:

HIV Medicine Association Guidelines Emphasize Primary Care Needs of People with HIV on ART

The HIV Medicine Association (HIVMA) of the Infectious Disease Society of America (IDSA) this week released new Primary Care Guidelines for the Management of Persons Infected with Human Immunodeficiency Virus, focusing on primary care and prevention for HIV positive people on effective antiretroviral therapy (ART). The new guidelines, published in the November 13, 2013, online edition of Clinical Infectious Diseases (in print January 2014) "reflect the fact that people with HIV are now living normal life spans," according to an HIVMA/IDSA press release.

alt

Read more:

HIV Integrase Inhibitor Elvitegravir Approved in European Union

The next-generation HIV integrase inhibitor elvitegravir has been approved by the European Commission, to be marketed under the brand name Vitekta, according to an announcement this week from developer Gilead Sciences. It is indicated for use in combination antiretriviral regimens containing a ritonavir-boosted protease inhibitor.

alt

Read more:

U.S. HIV Treatment Guidelines Expand Integrase Inhibitor Recommendations

The U.S. Department of Health and Human Services antiretroviral therapy guidelines panel has updated its list of preferred regimens for first-line treatment to include 2 additional HIV integrase inhibitors, elvitegravir (part of the Stribild single-tablet regimen) and dolutegravir (Tivicay).

alt

Read more: